

21 ⁸Department of Emergency Medicine, Massachusetts General Hospital and Harvard Medical 22 School, Boston, Massachusetts

- 23 Equal contribution
- 24 $\text{``To whom correspondence should be addressed: Sayon Dutta, MD (sduta1@partners.org) and}$

25 Rakesh K. Jain, PhD (jain@steele.mgh.harvard.edu)

26 **Short title:** Comparing machine learning algorithms in COVID-19

27

28 **Abstract (150 words)**: As predicting the trajectory of COVID-19 disease is challenging, 29 machine learning models could assist physicians determine high-risk individuals. This study 30 compares the performance of 18 machine learning algorithms for predicting ICU admission and 31 mortality among COVID-19 patients. Using COVID-19 patient data from the Mass General 32 Brigham (MGB) healthcare database, we developed and internally validated models using 33 patients presenting to Emergency Department (ED) between March-April 2020 (n = 1144) and 34 externally validated them using those individuals who encountered ED between May-August 35 2020 (n = 334). We show that ensemble-based models perform better than other model types at 36 predicting both 5-day ICU admission and 28-day mortality from COVID-19. CRP, LDH, and 37 procalcitonin levels were important for ICU admission models whereas eGFR <60 $m/min/1.73m^2$, ventilator use, and potassium levels were the most important variables for 39 predicting mortality. Implementing such models would help in clinical decision-making for 40 future COVID-19 and other infectious disease outbreaks.

- 41 **[Main Text: 3422 words]**
- 42 **Introduction**

43 The COVID-19 pandemic has led to significant morbidity and mortality throughout the 44 world $\frac{1}{2}$. The rapid spread of SARS-CoV-2 has provided limited time to identify factors involved 45 in SARS-CoV-2 transmission, predictors of COVID-19 severity, and effective treatments. At the 46 height of the pandemic, areas with high number of SARS-CoV-2 infections were resource-47 limited and forced to ration life-saving therapies such as ventilators and dialysis machines 2,3 . In 48 this setting, being able to identify patients requiring intensive care or at high risk of mortality 49 upon presentation to the hospital may help providers expedite patients to the most appropriate 50 care setting.

51 Model predictions are gaining increasing interest in clinical medicine. Machine learning 52 applications have been used to help predict acute kidney injury 4 and septic shock 5 , amongst 53 other outcomes in hospitalized patients. These tools have also been applied to outpatients to predict outcomes such as heart failure progression 6 . Machine learning tools can be applied to predict outcomes such as Intensive Care Unit (ICU) admission and mortality $\frac{7}{1}$. Thus far there 56 have been few studies that examined specific machine learning algorithms in predicting 57 outcomes such as mortality in COVID-19 patients $8-10$. Given the potential utility of machine 58 learning-based decision rules and the urgency of the pandemic, a concerted effort is being made to identify which machine learning applications are optimal for given sets of data and diseases $¹¹$.</sup>

60 To address this knowledge gap, we conducted a multi-hospital cohort (Mass General Brigham 61 (MGB) healthcare database) study to extensively evaluate the performance of 18 different 62 machine learning algorithms in predicting ICU admission and mortality. Our goal was to identify 63 the best prognostication algorithm using demographic data, comorbidities, and laboratory 64 findings of COVID-19 patients who visited emergency departments (ED) at MGB between 65 March and April 2020. We validated our models on a temporally distinct patient cohort that

68 **Results**

69 *Patient characteristics.*

70 We obtained data from 10,826 patients in the multihospital database (Massachusetts 71 General Brigham Healthcare database) who had COVID-19 infection during the period of March 72 and April 2020. A total of 3,713 out of the 10,826 patients visited EDs. We evaluated patients 73 based on demographics, medication use, history of past illness, clinical features, and laboratory 74 values described in Table S1. After excluding patients with missing data, 1,144 patients 75 remained, 99% of which were in-patients ($n = 1133$). For external validation, we pulled data of 76 temporally distinct individuals from the Mass General Brigham (MGB) healthcare database who 77 were positive for SARS-CoV-2 between May and August 2020. During this period, 1,754 out of 78 8,013 SARS-CoV-2 positive individuals visited the ER. After excluding patients with missing 79 variables from Table S1, a total of 334 patients were left (98% of which were in-patients).

80 The baseline characteristics of 1,144 patients in the training dataset are listed in Table 1. 81 The overall study population included 45% women, and the majority were above the age of 60. 82 The number of patients who were admitted to ICU within 5 days and who died within 28 days of 83 ED visit were 342 (30%) and 217 (19%), respectively. The external validation dataset included 84 patients with similar distribution in age ≥ 50 years ($X^2_{(4, N=1193)} = 8.9$, p = 0.063), gender ($X^2_{(1, N=193)}$ 85 $_{1478)}$ = 0.017, p = 0.89), race $(X^2_{(1, N = 1478)} = 0.07, p = 0.79)$ and BMI $(X^2_{(2, N = 1478)} = 4.31, p =$ 86 0.12) (Table S6). Of the 334 patients who visited the ED, 74 (22%) were admitted to the ICU 87 and 45 (13%) died with COVID-19.

88 *Comparing performance of prediction models – cross validation.*

89 We evaluated 18 machine learning algorithms belonging to 9 broad categories, namely 90 ensemble, Gaussian process, linear, naïve bayes, nearest neighbor, support vector machine, tree-91 based, discriminant analysis and neural network models.

92 On comparing the ICU admission prediction models using cross validation, we observed 93 that all ensemble-based models had mean precision-recall area under curve (PR AUC) scores 94 more than 0.77 (Table 2; Fig. S2A-B). Specifically, the PR AUC score for *AdaBoostClassifier* 95 was 0.80 (95% CI, 0.73 – 0.87), for *BaggingClassifier* was 0.80 (95% CI, 0.73 – 0.87), for 96 *GradientBoostingClassifier* was 0.77 (95% CI, 0.68 – 0.86), for *RandomForestClassifier* was 97 0.80 (95% CI, 0.70 – 0.90), for *XGBClassifier* was 0.78 (95% CI, 0.70 – 0.86), and for 98 *ExtraTreesClassifier* was [0.79 (95% CI, 0.72 – 0.86)]. In addition, *LogisticRegression* [0.79 99 (95% CI, 0.71 – 0.87)], and *LinearDiscriminantAnalysis* [0.76 (95% CI, 0.68 – 0.84)] also had 100 high PR AUC scores. In contrast, *GaussianProcessClassifier* [0.6 (95% CI, 0.54 – 0.66)], 101 *SGDClassifier* [0.63 (95% CI, 0.60 – 0.66)] and LinearSVC [0.65 (95% CI, 0.57 – 0.73)] had 102 low PR AUC scores. Upon performing multiple comparison analysis between all models (based 103 on PR AUC and ROC AUC scores), the ensemble-based models and *LogisticRegression* models 104 have similar pattern of performance (Fig. S1A-B). On grouping the models based on their broad 105 categories, we found that ensemble models have significantly higher PR AUC scores than all 106 other model types except for logistic regression (based on Fisher's Least Significant Difference 107 (LSD) t-test; Fig. 2A; details of statistical analysis in Table S7). For ROC AUC scores, ensemble 108 models performed better than all models except logistic regression (Fig. 2A; Table S7).

109 On comparing the mortality prediction models using cross validation, all ensemble-based 110 models had mean PR AUC scores higher than 0.8 (Table 3; Fig. S2C-D). The PR AUC score for 111 *AdaBoostClassifier* was 0.81 (95% CI, 0.76 – 0.86), for *BaggingClassifier* was 0.81 (95% CI, 112 0.74 – 0.88), for *GradientBoostingClassifier* was 0.81 (95% CI, 0.73 – 0.89), for 113 *RandomForestClassifier* was 0.8 (95% CI, 0.75 – 0.85), for *XGBClassifier* was 0.82 (95% CI, 114 0.75 – 0.89), and ExtraTreesClassifier [0.82 (95% CI, 0.74 – 0.90)]. In addition, 115 *LinearDiscriminantAnalysis* [0.85 (95% CI, 0.79 – 0.91)] also had a high PR AUC score. 116 However, for mortality prediction, *LogisticRegression* [0.73 (95% CI, 0.62 – 0.84)] had low PR 117 AUC score when compared to ensemble methods. The lowest PR AUC scores were for 118 *GaussianProcessClassifier* [0.55 (95% CI, 0.42 – 0.68)], *SGDClassifier* [0.54 (95% CI, 0.49 – 119 0.59)], Perceptron [0.6 (95% CI, 0.53 – 0.67)], and *KNeighborsClassifier* [0.6 (95% CI, 0.52 – 120 0.68)]. Upon performing multiple comparison analysis between all models (based on PR AUC 121 and ROC AUC scores), the ensemble-based models and *LinearDiscriminantAnalysis* models had 122 similar patterns of performance (Fig. S1C-D). When we grouped the models based on their broad 123 categories and compared their PR AUC and ROC AUC scores, we found that ensemble-based 124 models perform better than all other model types except Naïve bayes and discriminant analysis 125 based methods (based on Fisher's Least Significant Difference (LSD) t-test; Fig. 2B; details of 126 statistical analysis in Table S7).

127 *Comparing performance of prediction models – internal and external validation.*

128 We then tested the internal validation dataset on ICU admission models and found that 129 ensemble methods (PR $AUC \geq 0.8$) and *LogisticRegression* (PR $AUC = 0.83$) had the best scores 130 (Table 2). However, for the external validation dataset, *BaggingClassifier*, ¹³¹*RandomForestClassifier* and *XGBClassifier* had better PR AUC scores (≥ 0.6) than other 132 ensemble models. *LogisticRegression* also performed comparably (PR AUC = 0.62) to well-133 performing ensemble methods with the external validation dataset.

134 On evaluating the performance of mortality models using internal validation dataset, 135 ensemble methods, naïve bayes, and discriminant analysis-based models outperformed other 136 models (PR AUC \geq 0.7) (Table 3). In the external validation dataset, although the PR AUC 137 scores were lower, *AdaBoostClassifier*, *BaggingClassifier*, and *RandomForestClassifier* had 138 better PR AUC scores $(≥ 0.37)$ than other models. Unlike ICU admission prediction, 139 *LogisticRegression* had a low score with internal and external validation datasets (PR AUC = 140 0.65 and 0.23, respectively).

141 Overall, we found that ensemble models performed well in predicting both ICU 142 admission and mortality for COVID-19 patients.

143 *Critical variables for predicting ICU admission and mortality.*

144 To investigate how individual variables in the machine learning models impact outcome 145 prediction, we performed SHAP analysis for the best models – namely random forest for the ICU 146 admission model and XGB classifier for the mortality prediction model. For the ICU admission 147 prediction models, C-reactive protein, procalcitonin, lactate dehydrogenase, and first respiratory 148 rate were directly proportional to risk of ICU admission (Fig. 2C-D), while lower values of the 149 first oxygen saturation reading and lymphocytes were associated with increased probability of 150 ICU admission. For mortality prediction models, use of ventilator, estimated glomerular filtration 151 rate less than 60 ml/min/1.72 m², age greater than 80 years, hyperkalemia and high procalcitonin 152 were associated with higher mortality while lower lymphocyte counts were associated with 153 increased probability of death (Fig. 2E-F).

154 **Discussion**

155 In this study, we evaluated the ability of various machine learning algorithms to predict 156 clinical outcomes such as ICU admission or mortality using data available from initial ER 157 encounter of COVID-19 patients. Based on our analysis of 18 algorithms, we found that 158 ensemble-based methods have moderately better performance than other machine learning 159 algorithms. Optimizing the hyperparameters (Tables S4 and S5) enabled us to achieve the best-160 performing ensemble models. We also identified variables that had the largest impact on the 161 performance of the models. We demonstrated that for predicting ICU admission, C-reactive 162 protein, LDH, procalcitonin, lymphocytes, neutrophils, oxygen saturation and respiratory rate are 163 among the top predictors, but for mortality prediction, eGFR $<$ 60 ml/min/1.73m², serum 164 potassium levels, use of ventilator, age, ALT and white blood cells are the leading predictors.

165 Our model detected that CRP, LDH, procalcitonin, eGFR< 60 ml/min/m2, serum 166 potassium levels, advanced age and ventilator use are indicative of a worse outcome, which 167 aligns with previous studies of ICU admission and mortality (Table S2). Multiple retrospective 168 studies showed that increased procalcitonin values were associated with high risk for severe 169 COVID-19 infection¹². The explanation behind this association is not clear. Increased 170 procalcitonin level in COVID -19 patients can suggest bacterial coinfection, a marker of severity 171 of ARDS and immune dysregulation¹³⁻¹⁵ but may also be a marker of the hyperinflammation 172 associated with COVID-19 severity. We also found reduced kidney function as the major risk 173 factor for ICU mortality. This result has been revealed by two previous studies in the literature, 174 indicating that patients on dialysis and with chronic kidney disease have a high risk of mortality 175 from COVID-19^{16,17}. Our study also highlighted serum potassium level as an important predictor 176 for mortality. This finding has not been reported in the literature to our knowledge, although one study has reported the high prevalence of hypokalemia among patients with COVID-19^{18} .

178 Potassium derangement is independently associated with increased mortality in ICU patients¹⁹. 179 Deviations in serum potassium levels in COVID-19 patients may suggest dysregulation of the 180 renin-angiotensin system²⁰ which has been suggested to also play a role in SARS-CoV-2 181 pathogenesis. This finding shows that the model aligns with previously reported clinically 182 relevant markers and also predicts new markers that emerged from our patient population.

183 Our study utilizes a multi-hospital cohort that has been developed and validated in 184 temporarily distinct subsets of the cohort. Multiple studies in the past using machine learning 185 methodology to study COVID-19 outcomes used only a few machine learning algorithms^{8-10,21,22}. 186 However, these studies were oriented toward identifying clinical features rather than determining 187 the best machine learning algorithm at predicting clinical outcomes, so only limited number of 188 models were tested. To our knowledge, this is the first study to quantitatively and systematically 189 compare 18 machine learning models through robust methodology encompassing all categories 190 of algorithms. We showed that ensemble-methods perform better than other methods in 191 predicting ICU admission and mortality from COVID-19. Ensemble methods are meta-192 algorithms that combine several different machine learning techniques into one unified predictive model (Table $S3)^{23}$, which could explain this improvement in performance. We have 194 also done exhaustive hyperparameter tuning to determine the best values. By performing SHAP 195 analysis, we showed how variables impact outcomes in black-box machine learning models. 196 Thus, our study is consistent with previous clinical study results, revealing similar clinical 197 predictors for ICU admission and mortality, utilizing higher-performing machine learning 198 models.

199 There are a number of limitations in our study. The lack of complete laboratory values 200 for all patients necessitated exclusion of a large number of patients and removal of some

201 variables in development of the models. As suggested by Jakobsen et al²⁴, imputation is not an 202 advisable method to handle missingness, when the percentage of missing data exceeds 40%. The 203 majority of individuals (>98%) included in our analysis were those patients who visited to ED 204 and subsequently became in-patients. In the patients excluded due to missingness, only \sim 40% of 205 the patients needed in-patient care. This discrepancy in severity might be the reason for lack of 206 laboratory values in excluded patients.

207 Another limitation is that, as some of the laboratory values may take hours to be reported, 208 the data may not be available until after the patient has transitioned out of the ER, decreasing the 209 utility of using these predictors in triaging patient disposition. Similarly, as the mortality model 210 uses ventilator use as a predictor, it requires ICU admission to be utilized and would not be valid 211 in an earlier phase of care.

212 We also observed that the predicting capability on the external cohort (imbalanced 213 dataset) was higher for ICU admission models in comparison to mortality models. This could be 214 due to the changes instated in the ICU during the later period of pandemic. The changes in the 215 treatment regimens might be affecting the mortality and thereby affecting the predictive power of 216 our models. Our cohort is based on the population from Southern New England region of United 217 States and includes two hospitals that are world-class academic centers, which could also limit 218 the versatility of the models. More elaborate studies based on this framework in other cohorts 219 would help validate our findings.

220 Our model development process and findings could be used by clinicians in gauging the 221 clinical course, particularly ICU admission, of an individual with COVID-19 during an ED 222 encounter. We would recommend using ensemble-based methods for developing clinical 223 prediction models. Our ensemble methods identified key features in patients, such as kidney

224 function, potassium, procalcitonin, CRP and LDH, that allowed us to predict clinical outcomes. 225 Deploying such models would augment the clinical decision-making process by allowing 226 physicians to identify potentially high-risk individuals and adjust their treatment accordingly.

227

- 228 **Methods**
- 229 *Study population*

230 Patients from the Mass General Brigham (MGB) healthcare system that were positive for 231 COVID-19 between March and August of 2020 and had an ED encounter were included. 232 Patients either had COVID-19 prior to the index ED visit or were diagnosed during that 233 encounter. MGB is an integrated health care system which encompasses 14 hospitals across the 234 New England area in the United States. COVID-19 positive patients were defined by the 235 COVID-19 infection status, a discretely recorded field in the Epic EHR (Epic, Inc., Verona, WI). 236 The COVID-19 infection status was added automatically if a SARS-CoV-2 PCR test was 237 positive, or by Infection Control personnel if the patient has a confirmed positive test from an 238 outside facility. This study was approved by the MGB Institutional Review Board.

239 *Data collection and covariate selection*

240 We queried the data warehouse of our EHR for patient-level data including 241 demographics, comorbidities, home medications, most recent outpatient recorded blood pressure, 242 and death date. For each hospital encounter we extracted vital signs, laboratory values, admitting 243 service, hospital length of stay, date of first ICU admission, amongst others. The patient's 244 problem list was extracted and transformed into a comorbidity matrix by using the "comorbidity" 245 R package 25 .

246 *Outcome definition*

247 The two primary outcomes used for developing the models were ICU admission within 5 248 days of ED encounter and mortality within 28 days of ED encounter. The beginning of the 249 prediction window began upon arrival to the ED.

250 *Model development*

251 As described in Table S1, we selected a reduced set of potential predictor variables from 252 previously published literature (Table S2). We used the same covariates in developing the ICU 253 admission and mortality models except for ventilator use which was added to mortality models 254 but excluded from ICU admission models. Age (10 year intervals), race (African American or 255 other), BMI, modified Charlson Comorbidity Index 26 , angiotensin converting enzyme 256 inhibitor/angiotensin receptor blocker (ACEi/ARB) use, hypertension (>140/90 mmHg), and 257 eGFR <60 ml/min were treated as categorical values. Patients with missing values for the 258 independent variables or obviously incorrect entries (e.g., one patient was listed with respiratory 259 rate of 75 breaths per minute) were excluded. Imputation was not advisable due to a high 260 percentage of missingness²⁴. Models were developed using the patients admitted during the 261 period of March and April 2020. For external validation, we used a temporally distinct cohort 262 consisting of patients admitted from May through August 2020. The data set was imbalanced 263 with significantly fewer patients who were admitted to the ICU or died due to COVID-19 264 compared with those who did not. For the purpose of developing and internally validating the 265 machine learning models, we randomly selected surviving patients who were not admitted to the 266 ICU and matched the number of patients who were admitted to the ICU or died ($n = 684$ for ICU 267 models and $n = 434$ for mortality models). From this group of patients, 70% ($n = 478$ for ICU

268 models and $n = 303$ for mortality models) were used for developing machine learning models 269 and the remaining 30% were used for internal validation.

270 A total of eighteen machine learning algorithms were tested, the descriptions of which are 271 available in Table S3. For every machine learning model, we used a three-step approach. First, 272 we made models using various combinations of tunable hyperparameters which are used to 273 control the learning process of algorithms. The hyperparameters that were adjusted depended on 274 the algorithm (outlined in Table S4). After developing these models for each combination of 275 hyperparameter, we tested the performance of each of these combinations using a cross 276 validation technique (number of folds $= 5$) during which a precision-recall area under curve (PR 277 AUC) score was considered to select the best hyperparameter (Table S5). PR AUC score 278 compares the positive predictive value (precision) and true positive rate (sensitivity or recall) of a 279 model. For grading the performance of models, we used PR AUC scores as this is more 280 applicable for datasets that are imbalanced. In our case, the external validation dataset remained 281 an imbalanced dataset.

282 *Evaluation of model performance*

283 Model performance evaluation was done in three parts. A *StratifiedKFold* technique of 284 cross validation was first used during model development. In this method, 20% of the patients 285 were excluded while training the model and the excluded patients were then used to test the 286 model. This was done in an iterative process. Each model was evaluated by calculating the 287 Receiver Operating Characteristic Area Under the Curve (ROC AUC), PR AUC, F1, recall, 288 precision, balanced accuracy, and Brier scores. To calculate the 95% confidence interval, we 289 used $t_{0.975, df = 4} = 2.776$ based on *t*-distribution for $n = 5$.

290 For the second level of validation, the model performance was evaluated on the 30% of 291 patients who were not used during development of the models. This cohort worked as an internal 292 validation dataset for these models. Finally, for the external validation, the cohort of patients 293 who presented to the ED between May and August 2020 was used (Table S6).

294 *Model interpretation using Shapley values*

295 For explaining the models, SHAP feature importance was reported based on Shapley 296 values 27 , details of which are outlined in the Supplementary Methods. SHAP values are useful to 297 explain "black-box" machine learning models which are otherwise difficult to interpret. SHAP 298 values for each patient feature explain the intensity and direction of impact on predicting the 299 outcome.

300 *Software*

301 Data cleaning and processing were performed with R (R Core Team, version 3.6.3) using the tidyverse and comorbidity packages $25,28,29$. Machine learning model development was done 303 using Python (details in Supplementary Methods)³⁰⁻³³. The programming code for R and Python 304 are available upon request addressed to the corresponding author (*jain@steele.mgh.harvard.edu*).

305 **Supplementary Materials**

306 Methods

307 Fig. S1. Matrix plots showing differential model performance

308 Fig. S2. ROC AUC and PR AUC plots

- 309 Table S1. Selection of patients and variable details used for developing and testing the models
- 310 Table S2. Risk factors identified for mortality and ICU admission in COVID-19 studies
- 311 Table S3. Description of machine learning algorithms
- 312 Table S4. Hyperparameters which were optimized for machine learning algorithms
- 313 Table S5. Best hyperparameter values for machine learning algorithms that were chosen after
- 314 tuning hyperparameters using *GridSearchCV* and *cross validation* technique.
- 315 Table S6. Characteristics of patients who visited the emergency room between May and August
- 316 2020 for COVID-19, that were used to evaluate the machine learning models as an external
- 317 dataset. Variables stratified based on ICU admission and death of patients.
- 318 Table S7. Multiple comparison between ensemble methods and other types of machine learning
- 319 algorithms using Fischer Least Significant Difference (LSD) t-test.

320 **References:**

- 321 1 WorldHealthOrganization. Coronavirus disease (COVID-19) : situation report, 182. (2020).
- 322 2 Antommaria, A. H. M. *et al.* Ventilator Triage Policies During the COVID-19 Pandemic at U.S. Hospitals
- 323 Associated With Members of the Association of Bioethics Program Directors. *Ann Intern Med* **173**, 188-
- 324 194, doi:10.7326/m20-1738 (2020).
- 325 3 Silberzweig, J. *et al.* Rationing Scarce Resources: The Potential Impact of COVID-19 on Patients with
- 326 Chronic Kidney Disease. *Journal of the American Society of Nephrology* **31**, 1926,
- 327 doi:10.1681/ASN.2020050704 (2020).

328 4 Tomasev, N. *et al.* A clinically applicable approach to continuous prediction of future acute kidney injury.

329 *Nature* **572**, 116-119, doi:10.1038/s41586-019-1390-1 (2019).

- 330 5 Henry, K. E., Hager, D. N., Pronovost, P. J. & Saria, S. A targeted real-time early warning score
- 331 (TREWScore) for septic shock. *Sci Transl Med* **7**, 299ra122, doi:10.1126/scitranslmed.aab3719 (2015).
- 332 6 Wehbe, R. M., Khan, S. S., Shah, S. J. & Ahmad, F. S. Predicting High-Risk Patients and High-Risk
- 333 Outcomes in Heart Failure. *Heart Fail Clin* **16**, 387-407, doi:10.1016/j.hfc.2020.05.002 (2020).
- 334 7 Subudhi, S., Verma, A. & B.Patel, A. Prognostic machine learning models for COVID-19 to facilitate
- 335 decision making. *International Journal of Clinical Practice*, e13685, doi:10.1111/ijcp.13685 (2020).
- 336 8 Yan, L. *et al.* An interpretable mortality prediction model for COVID-19 patients. *Nature Machine*

337 *Intelligence* **2**, 283-288, doi:10.1038/s42256-020-0180-7 (2020).

- 338 9 Iwendi, C. *et al.* COVID-19 Patient Health Prediction Using Boosted Random Forest Algorithm. *Front* 339 *Public Health* **8**, 357, doi:10.3389/fpubh.2020.00357 (2020).
- 340 10 Wu, G. *et al.* Development of a clinical decision support system for severity risk prediction and triage of 341 COVID-19 patients at hospital admission: an international multicentre study. *Eur Respir J* **56**,
- 342 doi:10.1183/13993003.01104-2020 (2020).
- 343 11 Eaneff, S., Obermeyer, Z. & Butte, A. J. The Case for Algorithmic Stewardship for Artificial Intelligence 344 and Machine Learning Technologies. *JAMA*, doi:10.1001/jama.2020.9371 (2020).
- 345 12 Lippi, G. & Plebani, M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A 346 meta-analysis. *Clin Chim Acta* **505**, 190-191, doi:10.1016/j.cca.2020.03.004 (2020).
- 347 13 Linscheid, P. *et al.* In vitro and in vivo calcitonin I gene expression in parenchymal cells: a novel product
- 348 of human adipose tissue. *Endocrinology* **144**, 5578-5584, doi:10.1210/en.2003-0854 (2003).
- 349 14 Muller, B. *et al.* Ubiquitous expression of the calcitonin-i gene in multiple tissues in response to sepsis. *J*
- 350 *Clin Endocrinol Metab* **86**, 396-404, doi:10.1210/jcem.86.1.7089 (2001).
- 351 15 Meisner, M. Update on procalcitonin measurements. *Ann Lab Med* **34**, 263-273,
- 352 doi:10.3343/alm.2014.34.4.263 (2014).
- 353 16 Williamson, E. J. *et al.* Factors associated with COVID-19-related death using OpenSAFELY. *Nature* **584**,
- 354 430-436, doi:10.1038/s41586-020-2521-4 (2020).

- 355 17 Flythe, J. E. *et al.* Characteristics and Outcomes of Individuals With Pre-existing Kidney Disease and
- 356 COVID-19 Admitted to Intensive Care Units in the United States. *Am J Kidney Dis*,
- 357 doi:10.1053/j.ajkd.2020.09.003 (2020).
- 358 18 Chen, D. *et al.* Assessment of Hypokalemia and Clinical Characteristics in Patients With Coronavirus
- 359 Disease 2019 in Wenzhou, China. *JAMA Netw Open* **3**, e2011122,
- 360 doi:10.1001/jamanetworkopen.2020.11122 (2020).
- 361 19 Hessels, L. *et al.* The relationship between serum potassium, potassium variability and in-hospital mortality
- 362 in critically ill patients and a before-after analysis on the impact of computer-assisted potassium control.
- 363 *Crit Care* **19**, 4, doi:10.1186/s13054-014-0720-9 (2015).
- 364 20 Weir, M. R. & Rolfe, M. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. *Clin*
- 365 *J Am Soc Nephrol* **5**, 531-548, doi:10.2215/CJN.07821109 (2010).
- 366 21 Yao, H. *et al.* Severity Detection for the Coronavirus Disease 2019 (COVID-19) Patients Using a Machine 367 Learning Model Based on the Blood and Urine Tests. *Front Cell Dev Biol* **8**, 683,
- 368 doi:10.3389/fcell.2020.00683 (2020).
- 369 22 Liang, W. *et al.* Early triage of critically ill COVID-19 patients using deep learning. *Nat Commun* **11**, 3543, 370 doi:10.1038/s41467-020-17280-8 (2020).
- 371 23 Dietterich, T. G. in *Proceedings of the First International Workshop on Multiple Classifier Systems* 1–15 372 (Springer-Verlag, 2000).
- 373 24 Jakobsen, J. C., Gluud, C., Wetterslev, J. & Winkel, P. When and how should multiple imputation be used
- 374 for handling missing data in randomised clinical trials a practical guide with flowcharts. *BMC Med Res*
- 375 *Methodol* **17**, 162, doi:10.1186/s12874-017-0442-1 (2017).
- 376 25 Gasparini, A. comorbidity: An R package for computing comorbidity scores. *Journal of Open Source* 377 *Software* **3**, 648, doi:10.21105/joss.00648 (2018).
- 378 26 Charlson, M. E., Pompei, P., Ales, K. L. & MacKenzie, C. R. A new method of classifying prognostic
- 379 comorbidity in longitudinal studies: development and validation. *J Chronic Dis* **40**, 373-383,
- 380 doi:10.1016/0021-9681(87)90171-8 (1987).
- 381 27 Lundberg, S. M. & Lee, S.-I. A Unified Approach to Interpreting Model Predictions. 4765--4774 (2017).

401 designed and built machine learning models. S.D. extracted data from the MGB database.

402 A.V., A.B.P., C.C.H., M.J.K., S.D., H.L., T.S., L.L.M., and R.K.J supervised model 403 development. All authors were involved in writing the article. **Competing interests**: 404 LLM owns equity in Bayer AG and is a consultant for SimBiosys. R.K.J. received 405 honorarium from Amgen; consultant fees from Chugai, Merck, Ophthotech, Pfizer, 406 SPARC, SynDevRx, XTuit; owns equity in Accurius, Enlight, Ophthotech, SynDevRx;

407 and serves on the Boards of Trustees of Tekla Healthcare Investors, Tekla Life Sciences 408 Investors, Tekla Healthcare Opportunities Fund, Tekla World Healthcare Fund. Neither 409 any reagent nor any funding from these organizations was used in this study. Other 410 coauthors have no conflict of interests to declare. **Data and materials availability**: The 411 programming code for R and Python are available upon request addressed to the 412 corresponding author (jain@steele.mgh.harvard.edu). 413 414 415 **Figures legends**: 416 417 **Fig. 1**. Schematic diagram representing the process of machine learning model development. **(A)** 418 Flow diagram depicting steps in obtaining the training and external validation datasets 419 (with patient numbers in each step). **(B)** The process of patient selection, dataset 420 balancing, hyperparameter tuning, cross-validation, internal and external validation are 421 shown. 422 423 **Fig. 2. (A-B). Boxplots** representing the precision recall area under the curve (PR AUC) and 424 receiver operating characteristic area under the curve (ROC AUC) scores of ICU 425 admission and mortality prediction models. Error bars indicate minimum and maximum 426 values. Statistical analysis was performed using Fisher's Least Significant Difference 427 (LSD) *t*-test. *p-*value style is geometric progression - <0.03 (*), <0.002 (**), <0.0002 428 (***), <0.0001 (****). **Variables of importance for ICU admission and mortality** 429 **prediction models.** (C) SHAP value summary dot plot and (D) variable of importance of 430 *RandomForest* algorithm-based ICU admission model. (E) SHAP value summary dot

431 plot and (F) variable of importance of *XGBClassifier* algorithm-based mortality model. 432 The calculation of SHAP values is done by comparing the prediction of the model with 433 and without the feature in every possible way of adding the feature to the model. The bar 434 plot depicts the mean SHAP values whereas the summary dot plot shows the impact on 435 the model. The color of the dot represents the value of the feature and the X-axis depicts 436 the direction and magnitude of the impact. Red colored dots represent high value of the 437 feature and the blue represents lower value. A positive SHAP value means the feature 438 value increases likelihood of ICU admission/mortality. For features with positive SHAP 439 value for red dots, suggests directly proportional variable to outcome of interest and those 440 with positive SHAP value for blue dots, suggest inverse correlation.

⁴⁴¹**Table 1.** Characteristics of patients who visited emergency department during March and April 2020 for COVID-19, that were

⁴⁴³**Table 2.** Performance of machine learning models to predict ICU admission within 5 days in COVID-19 patients. Cross-validation

444 scores are expressed as mean ± 95% confidence interval.

⁴⁴⁵**Table 3.** Performance of machine learning models to predict mortality within 28 days in COVID-19 patients. Cross-validation scores

446 are expressed as mean \pm 95% confidence interval.

medRxiv preprint doi: https://doi.org/10.1101/2020.11.20.20235598; this version posted November 23, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has grante preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this included November 23, 2020. [;](https://doi.org/10.1101/2020.11.20.20235598) https://doi.org/10.1101/2020. ; 12020. ; https://doi.org/10.1101/2020. ; https://doi.org/10.11.2020. ; this version posted November 23, 2020. In a copyright rolat All rights reserved. No reuse allowed without permission.

447

Figure 2

Model type

RandomForest model for predicting ICU admission

C-reactive protein Procalcitonin Lactate dehydrogenase Lymphocytes Neutrophils First oxygen saturation First respiratory rate Calcium Ferritin Alanine aminotransferase Sodium Hemoglobin Chloride Blood glucose level White blood cells First heart rate Anion gap D-dimer Female gender

XGBoost model for predicting death

Use of ventilator GFR less than 60 ml/min/1.72m2 Potassium Age group: 80-89 Age group: 90+ Alanine aminotransferase White blood cells First heart rate Procalcitonin First respiratory rate C-reactive protein History of congestive heart failure Lymphocytes Sodium Hemoglobin Age group: 70-79 Blood glucose level History of dementia Neutrophils On anticoagulant

